Join today and begin receiving all the benefits of ASA membership.
The ASAPAC provides political support for ASA's advocacy efforts and allows our members to participate in the political process.
ASA offers access to standards, guidelines, statements and practice parameters that are based on the most up-to-date scientific evidence.
ASA offers resources to help you navigate MACRA.
Simulation anesthesia education in a virtual online environment available anytime, anywhere.
Learn from experts and leaders in anesthesia about the critical skills needed to stay at the forefront of anesthesia practice management.
Promoting scientific discovery and knowledge in perioperative, critical care, and pain medicine to advance patient care.
Gain assistance in PSH Pilot implementation, optimization of a PSH Pilot, expansion of a PSH Pilot to new service lines or system-wide conversion. Applications are due April 15.
Background: Preoperative administration of the antifibrinolytic agent tranexamic acid reduces bleeding in patients undergoing hip arthroplasty. Increased fibrinolytic activity is maintained throughout the first day postoperation. The objective of thestudy was to determine whether additional perioperative administration of tranexamic acid would further reduce blood loss.
Methods: This prospective, double-blind, parallel-arm, randomized, superiority study was conducted in 168 patients undergoing unilateral primary hip arthroplasty. Patients received a preoperative intravenous bolus of 1 g of tranexamic acid followed by a continuous infusion of either tranexamic acid 1 g (bolus-plus-infusion group) or placebo (bolus group) for 8 h. The primary outcome was calculated perioperative blood loss up to day 5. Erythrocyte transfusion was implemented according to a restrictive transfusion trigger strategy.
Results: The mean perioperative blood loss was 919 ± 338 ml in the bolus-plus-infusion group (84 patients analyzed) and 888 ± 366 ml in the bolus group (83 patients analyzed); mean difference, 30 ml (95% CI, -77 to 137; P = 0.58). Within 6 weeks postsurgery, three patients in each group (3.6%) underwent erythrocyte transfusion and two patients in the bolus group experienced distal deep-vein thrombosis. A meta-analysis combining data from this study with those of five other trials showed no incremental efficacy of additional perioperative administration of tranexamic acid.
Conclusions: A preoperative bolus of tranexamic acid, associated with a restrictive transfusion trigger strategy, resulted in low erythrocyte transfusion rates in patients undergoing hip arthroplasty. Supplementary perioperative administration of tranexamic acid did not achieve any further reduction in blood loss.
CME Credit: 1.00 AMA PRA Category 1 Credit™
Required Hardware / Software:Adobe Acrobat Reader, Internet connection. Web browser version must have been released within the last three years.
Activity Release Date:08/15/2017
Activity Expiration Date:08/14/2020
Learning Objectives: After successfully completing this activity, the learner will be able to:
- Inform patients of the benefits of using tranexamic acid (TXA) to reduce blood loss (1, 3)- Determine the best method of TXA administration for a specific patient during hip surgery (4, 5, 6)- Advise...
- Inform patients of the benefits of using tranexamic acid (TXA) to reduce blood loss (1, 3)- Determine the best method of TXA administration for a specific patient during hip surgery (4, 5, 6)- Advise the patient on the risks associated with the use of TXA (2, 3, 4, 5)
Faculty and Credentials
Editor-in-Chief: Evan D. Kharasch, M.D., Ph.D., has reported receiving consulting fees from TEN Healthcare.
CME Editors: Leslie C. Jameson, M.D. has reported no relevant financial relationships with commercial interests. Dan J. Kopacz, M.D., has reported holding an equity position with SoloDex, LLC.
Authors: Paul J. Zufferey, M.D., Ph.D; Julien Lanoiselée, M.B.B.S.; Céline Chapelle, M.Sc.; Dmitry B. Borisov, M.D.; Jean-Yves Bien, M.D.; Pierre Lambert, M.D.; Rémi Philippot, M.D., Ph.D.; Serge Molliex, M.D., Ph.D.; Xavier Delavenne, Pharm.D., Ph.D.; Susan M. Goobie, M.D., F.R.C.P.C.; and Steven M. Frank, M.D., report no relevant financial relationships with commercial interests.
ASA Staff: Kari L. Lee, Senior Managing Editor, has reported no relevant financial relationships with commercial interests. Ginger Clark, Senior Editor, has an equity position in Merck & Co.
Disclosure StatementThe American Society of Anesthesiologists remains strongly committed to providing the best available evidence-based clinical information to participants of this educational activity and requires an open disclosure of any potential conflict of interest identified by our faculty members. It is not the intent of the American Society of Anesthesiologists to eliminate all situations of potential conflict of interest, but rather to enable those who are working with the American Society of Anesthesiologists to recognize situations that may be subject to question by others. All disclosed conflicts of interest are reviewed by the educational activity course director/chair to ensure that such situations are properly evaluated and, if necessary, resolved. The American Society of Anesthesiologists educational standards pertaining to conflict of interest are intended to maintain the professional autonomy of the clinical experts inherent in promoting a balanced presentation of science. Through our review process, all American Society of Anesthesiologists CME activities are ensured of independent, objective, scientifically balanced presentations of information. Disclosure of any or no relationships will be made available for all educational activities.
The information provided at this CME activity is for continuing education purposes only and is not meant to substitute for the independent medical judgment of a healthcare provider relative to diagnostic and treatment options of a specific patient’s medical condition.
Core Competencies: Medical knowledge
Target Audience: ANESTHESIOLOGY Journal CME is intended for anesthesiologists. Researchers and other health care professionals with an interest in anesthesiology may also participate.
CME Credit: 1.00 AMA PRA Category 1 Credit™
The American Society of Anesthesiologists is accredited by the Accreditation Council for Continuing Medical Education to provide continuing medical education for physicians.
The American Society of Anesthesiologists designates this journal-based CME activity for a maximum of 1.00 AMA PRA Category 1 Credit(s)™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.
1.00 Non-physician Credit Non-physicians may receive a Certificate of Completion stating that this activity was designated for 1.00 AMA PRA Category 1 Credit(s)™.
Activity Release Date: 8/15/2017 Activity Expiration Date: 8/14/2020
Whose contributions allow the American Society of Anesthesiologists® to create world-class education and resources to improve patient care and outcomes.
1061 American Lane
Schaumburg, IL 60173-4973
telephone: (847) 825-5586
fax: (847) 825-1692
905 16th Street, N.W.
Washington, D.C. 20006
telephone: (202) 289-2222
fax: (202) 371-0384
© 2018 American Society of Anesthesiologists (ASA), All Rights Reserved.
Privacy Statement | Site Map | Terms and Conditions